[1]季亚香,奚 静,刘春艳,等.基于天冬氨酸转氨酶-血小板计数比的列线图模型对肝细胞癌射频消融治疗后复发的预测价值[J].介入放射学杂志,2024,33(01):39-43.
　JI Yaxiang,XI Jing,LIU Chunyan,et al.The predictive value of a nomogram model based on aspartate aminotransferase-platelet ratio index for hepatocellular carcinoma recurrence after radiofrequency ablation[J].journal interventional radiology,2024,33(01):39-43.
点击复制

基于天冬氨酸转氨酶-血小板计数比的列线图模型对肝细胞癌射频消融治疗后复发的预测价值()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年01
页码:
39-43
栏目:
非血管介入
出版日期:
2024-01-31

文章信息/Info

Title:
The predictive value of a nomogram model based on aspartate aminotransferase-platelet ratio index for hepatocellular carcinoma recurrence after radiofrequency ablation
作者:
季亚香;  奚 静;  刘春艳;  吴 萍;  章晓兰;  宋 蒨
Author(s):
JI Yaxiang;  XI Jing;  LIU Chunyan;  WU Ping;  ZHANG Xiaolan;  SONG Qian.
Department of Ultrasound， Wujin Hospital Affiliated to Jiangsu University（Wujin Clinical College of Xuzhou Medical University）， Changzhou， Jiangsu Province 213000， China
关键词:
【关键词】 肝细胞癌;  射频消融;  天冬氨酸转氨酶-血小板计数比值指数;  复发;  列线图
文献标志码:
A
摘要:
【摘要】 目的 探讨天冬氨酸转氨酶-血小板计数比值指数（aspartate aminotransferase-platelet ratio index，APRI）与肝细胞癌（hepatocellular carcinoma，HCC）射频消融（radiofrequency ablation，RFA）治疗后肿瘤复发的关系。方法 纳入2017年1月至2020年12月江苏大学附属武进医院初诊为HCC并接受RFA治疗的患者204例。采用受试者工作特征（receiver operation characteristics， ROC）曲线确定APRI的最佳截断值。绘制Kaplan-Meier曲线计算高、低APRI组患者的无复发生存期（recurrence-free survival， RFS）。Cox回归分析RFA后HCC复发的独立预测因素，并选择显著变量构建列线图模型。通过一致性指数（concordance index，C-index）和校正曲线评价列线图模型对HCC复发的预测能力。结果 RFA治疗后HCC复发率为57.4%（117/204）。APRI预测HCC复发的最佳截断值为0.501，曲线下面积（area under curve， AUC）为0.678 （95%CI：0.603～0.752）。高APRI组（≥0.501）121例，低APRI组（＜0.501）83例，高APRI与患者低RFS显著相关 （χ２=12.929， P＜0.01）。Cox回归分析证实，肿瘤数目（HR=1.541， 95% CI：1.039～2.286， P=0.031）、肿瘤最大直径（HR=1.461， 95% CI：1.011～2.112， P=0.044）、血清AFP（HR=2.286， 95%CI：1.576～3.318， P＜0.01）和APRI（HR=1.873， 95% CI：1.257～2.790， P=0.002）是HCC复发的独立风险因素。基于以上4个因素构建预测RFA治疗后HCC复发的列线图模型，C-index为0.769 （95% CI：0.676～0.862），预测1年、2年和3年RFS的AUC分别为0.707、0.719和0.707。校正曲线展示模型预测与实际复发风险之间具有良好一致性。结论 基于APRI与肿瘤生物学特征的列线图模型对HCC复发具有良好预测能力。

参考文献/References:

［1］ Xia Y， Li J， Liu G， et al. Long- term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma： a randomized clinical trial［J］. JAMA Oncol， 2020， 6： 255- 263.
［2］ Kim S， Yoon CJ， Cho JY， et al. Comparative long- term outcomes of laparoscopic hepatectomy and radiofrequency ablation for hepatocellular carcinoma located in the anterolateral segments of the liver［J］. J Hepatobiliary Pancreat Sci，2022，29：349- 358.
［3］ Pan YX， Long Q， Yi MJ， et al. Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma： a real world single center study［J］. Eur J Surg Oncol， 2020， 46： 548- 559.
［4］ Zhang C， Wu J， Xu J， et al. Association between aspartate aminotransferase- to- platelet ratio index and hepatocellular carcinoma risk in patients with chronic hepatitis： a meta- analysis of cohort study［J］. Dis Markers， 2019，2019： 2046825.
［5］ Ji F， Zhou R， Wang W， et al. High post- treatment α- fetoprotein levels and aspartate aminotransferase- to- platelet ratio index predict hepatocellular carcinoma in hepatitis C virus decompensated cirrhotic patients with sustained virological response after antiviral therapy［J］. J Interferon Cytokine Res， 2017， 37： 362- 368.
［6］ Yugawa K， Maeda TKH， Nagata S， et al. Impact of aspartate aminotransferase- to- platelet ratio index based score to assess posthepatectomy liver failure in patients with hepatocellular carcninoma［J］. World J Surg Oncol， 2022， 20： 248.
［7］ Mai RY， Ye JZ， Long ZR， et al. Preoperative aspartate aminotransferase- to- platelet- ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma［J］. Cancer Manag Res， 2019， 11： 1401- 1414.
［8］ Yugawa K， Maeda TKH， Nagata S， et al. A novel combined prognostic nutritional index and aspartate aminotransferase- to- platelet ratio index- based score can predict the survival of patients with hepatocellular carcinoma who undergo hepatic resection［J］. Surg Today， 2022， 52： 1096- 1108.
［9］ Allenson K， Roife D， Kao LS， et al. Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index［J］. J Gastrointest Oncol， 2020， 11： 291- 297.
［10］ Matsumoto M， Wakiyama S， Shiba H， et al. Usefulness of aspartate aminotransferase to platelet ratio index as a prognostic factor following hepatic resection for hepatocellular carcinoma［J］. Mol Clin Oncol， 2018， 9： 369- 376.
［11］ Johnson PJ， Berhane S， Kagebayashi C， et al. Assessment of liver function in patients with hepatocellular carcinoma： a new evidence- based approach- the ALBI grade［J］. J Clin Oncol， 2015， 33： 550- 558.
［12］ Lu ZH，Sun Z，Liu CY，et al. Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation： a retrospective cohort study［J］. BMC Cancer， 2021， 21： 751.
［13］ Kim CG， Lee HW， Choi HJ， et al. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation［J］. Cancer Med， 2019， 8： 5023- 5032.
［14］ Xiao G， Yang J， Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis- 4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection： a systemic review and meta- analysis［J］. Hepatology， 2015， 61： 292- 302.
［15］ Sookoian S， Pirola CJ. Liver enzymes，metabolomics and genome- wide association studies： from systems biology to the personalized medicine［J］. World J Gastroenterol， 2015， 21： 711- 725.
［16］ Kondo R， Yano H， Nakashima O， et al. Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C［J］. J Gastroenterol， 2013， 48： 526- 534.
［17］ Peck- Radosavljevic M. Thrombocytopenia in chronic liver disease［J］. Liver Int， 2017， 37： 778- 793.
［18］ Ho- Tin- Noe B， Carbo C， Demers M， et al. Innate immune cells induce hemorrhage in tumors during thrombocytopenia［J］. Am J Pathol， 2009， 175： 1699- 1708.
［19］ Lai L， Su T， Liang Z， et al. Development and assessment of novel predictive nomograms based on APRI for hepatitis B virus- associated small solitary hepatocellular carcinoma with stereotactic body radiotherapy［J］. J Cancer， 2020， 11： 6642- 6652.
［20］ Tang T， Qiu JL， Li GW， et al. Aspartate aminotransferase- to- platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients［J］. Clin Radiol， 2018， 73： 259- 265.
［21］ Shen SL， Fu SJ， Chen B， et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B- induced hepatocellular carcinoma after hepatic resection［J］. Ann Surg Oncol， 2014， 21： 3802- 3809.
［22］ Lee JI， Lee HW， Kim SU， et al. Follow- up liver stiffness measurements after liver resection influence oncologic outcomes of hepatitis- B- associated hepatocellular carcinoma with liver cirrhosis［J］. Cancers（Basel）， 2019， 11： 425.
［23］ Zhu GQ， Wang K， Wang B， et al. Aspartate aminotransferase- to- platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization［J］. Cancer Manag Res， 2019， 11： 63- 79.
［24］ Zhang X， Svn Z， Liv MS， et al. Assessment of prognostic value of aspartate aminotransferase- to- platelet ratio index in patients with hepatocellular carcinoma： meta- analysis of 28 cohort studies［J］. Front Med（Lausanne）， 2021， 8： 756210.
［25］ 张 磊，侯忠衡，王 祁，等． 经肝动脉化疗栓塞治疗中期肝癌预后的预测模型的建立和验证［J］． 介入放射学杂志， 2021， 30：1236- 1242．
［26］ Nault JC， Sutter O， Nahon P， et al. Percutaneous treatment of hepatocellular carcinoma： state of the art and innovations［J］. J Hepatol， 2018， 68： 783- 797.
［27］ Fujiwara N， Friedman SL， Goossens N， et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine［J］. J Hepatol， 2018， 68： 526- 549.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(01):177.
[2]蒲红.上海市第二届射频消融疑难病例研讨会纪要[J].介入放射学杂志,1997,(01):63.
[3]蒲红,尹炯,王咏梅,等.显性间隔房室旁路的射频消融[J].介入放射学杂志,1997,(02):104.
[4]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(01):333.
[5]罗荣光,黄金华.肿瘤射频消融：电极的类型和消融灶的特点[J].介入放射学杂志,2011,(02):159.
　LUO Rong-guang,HUANG Jin-hua..Radiofrequency ablation of tumors: the relationship between the electrode type and the feature of ablated zone[J].journal interventional radiology,2011,(01):159.
[6]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(01):206.
[7]程洪涛,郭晨阳,黎海亮,等.ＴＡＣＥ联合射频消融治疗原发性肝癌疗效的影响因素分析[J].介入放射学杂志,2012,(03):216.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ＣＴｇｕｉｄｅｄ ｐｅｒｃｕｔａｎｅｏｕｓ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｔｈｅ ｔｒｅａｔｍｅｎｔ ｏｆ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａｎ ａｎａｌｙｓｉｓ ｏｆ ｆａｃｔｏｒｓ ａｆｆｅｃｔｉｎｇ ｔｈｅ ｔｈｅｒａｐｅｕｔｉｃ ｒｅｓｕｌｔ [J].journal interventional radiology,2012,(01):216.
[8]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合ＣＴ引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
　,,et al.Ｓｅｑｕｅｎｔｉａｌ ｔｒｅａｔｍｅｎｔ ｗｉｔｈ ＴＡＣＥ ａｎｄ ＣＴｇｕｉｄｅｄ ＲＦＡ ｆｏｒ ｓｍａｌｌ ａｎｄ ｍｏｄｅｒａｔｅ ｓｉｚｅｄ ＨＣＣ [J].journal interventional radiology,2012,(01):301.
[9]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(01):322.
[10]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(01):469.
[11]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(01):908.
[12]王晓维,付守忠,戴 锋,等.肝动脉栓塞化疗联合射频消融与联合微波消融治疗原发性肝癌的疗效和安全性比较 [J].介入放射学杂志,2016,(08):673.
　WANG Xiao-wei,FU Shou-zhong,DAI Feng,et al.The curative effect and safety in treating primary hepatocellular carcinoma: comparison between TACE plus radiofrequency ablation and TACE plus microwave ablation [J].journal interventional radiology,2016,(01):673.
[13]徐晓林,朱争艳,经 翔.肝细胞癌患者射频消融前后的免疫状态研究进展[J].介入放射学杂志,2017,(01):87.
　XU Xiao- lin,ZHU Zheng- yan,JING Xiang.The immune state in patients with hepatocellular carcinoma before and after radiofrequency ablation treatment： recent progress in research[J].journal interventional radiology,2017,(01):87.
[14]郝美君,刘 凯,郭向华,等.射频消融亚致死性温度对肝癌干细胞的影响 [J].介入放射学杂志,2017,(07):636.
　HAO Meijun,LIU Kai,GUO Xianghua,et al.The effect of radiofrequency ablation with sublethal temperature on the stem cells of hepatocellular carcinoma[J].journal interventional radiology,2017,(01):636.
[15]刘 毅,卓 琳,朱 蓓,等.肝动脉化疗栓塞联合经皮消融治疗肝细胞癌疗效的meta分析 [J].介入放射学杂志,2017,(09):830.
　LIU Yi,ZHUO Lin,ZHU Bei,et al.Transcatheter arterial chemoembolization in combination with percutaneous ablation therapy for the treatment of hepatocellular carcinoma： a meta- analysis[J].journal interventional radiology,2017,(01):830.
[16]龙 江,赵 鹏,杨晓珍,等.射频消融治疗中等肝细胞癌5年预后及影响因素分析 [J].介入放射学杂志,2019,28(04):343.
　LONG Jiang,ZHAO Peng,YANG Xiaozhen,et al.Radiofrequency ablation for the treatment of medium- sized hepatocellular carcinomas： analysis of 5- year prognosis and influencing factors[J].journal interventional radiology,2019,28(01):343.
[17]彭建扬,翁志成,吴伟达,等.3.0T MR引导下肝细胞癌射频消融术的可行性研究[J].介入放射学杂志,2019,28(11):1062.
　PENG Jianyang,WENG Zhicheng,WU Weida,et al.Feasibility study of 3.0T MR-guided radiofrequency ablation for hepatocellular carcinoma[J].journal interventional radiology,2019,28(01):1062.

备注/Memo

备注/Memo:
（收稿日期：2023- 02- 28）
（本文编辑：新 宇）
更新日期/Last Update: 2024-01-30